1. Home
  2. ADVM vs SRL Comparison

ADVM vs SRL Comparison

Compare ADVM & SRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • SRL
  • Stock Information
  • Founded
  • ADVM 2006
  • SRL 2017
  • Country
  • ADVM United States
  • SRL China
  • Employees
  • ADVM N/A
  • SRL N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • SRL Professional Services
  • Sector
  • ADVM Health Care
  • SRL Consumer Discretionary
  • Exchange
  • ADVM Nasdaq
  • SRL Nasdaq
  • Market Cap
  • ADVM 98.0M
  • SRL 115.0M
  • IPO Year
  • ADVM 2014
  • SRL N/A
  • Fundamental
  • Price
  • ADVM $4.50
  • SRL $7.70
  • Analyst Decision
  • ADVM Strong Buy
  • SRL
  • Analyst Count
  • ADVM 6
  • SRL 0
  • Target Price
  • ADVM $27.83
  • SRL N/A
  • AVG Volume (30 Days)
  • ADVM 189.1K
  • SRL 4.6K
  • Earning Date
  • ADVM 03-21-2025
  • SRL 04-28-2025
  • Dividend Yield
  • ADVM N/A
  • SRL 3.35%
  • EPS Growth
  • ADVM N/A
  • SRL N/A
  • EPS
  • ADVM N/A
  • SRL N/A
  • Revenue
  • ADVM $1,000,000.00
  • SRL $33,997,735.00
  • Revenue This Year
  • ADVM N/A
  • SRL N/A
  • Revenue Next Year
  • ADVM $1,162.55
  • SRL N/A
  • P/E Ratio
  • ADVM N/A
  • SRL N/A
  • Revenue Growth
  • ADVM N/A
  • SRL N/A
  • 52 Week Low
  • ADVM $3.52
  • SRL $5.74
  • 52 Week High
  • ADVM $18.50
  • SRL $9.99
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 51.62
  • SRL 46.93
  • Support Level
  • ADVM $4.20
  • SRL $7.30
  • Resistance Level
  • ADVM $4.91
  • SRL $7.82
  • Average True Range (ATR)
  • ADVM 0.49
  • SRL 0.21
  • MACD
  • ADVM 0.06
  • SRL -0.02
  • Stochastic Oscillator
  • ADVM 60.49
  • SRL 47.06

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

Share on Social Networks: